Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 156

Similar articles for PubMed (Select 21041380)

1.

Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy.

Tuccori M, Focosi D, Blandizzi C, Pelosini M, Montagnani S, Maggi F, Pistello M, Antonioli L, Fornai M, Pepe P, Rossi G, Petrini M.

Oncologist. 2010;15(11):1214-9. doi: 10.1634/theoncologist.2010-0098. Epub 2010 Nov 1.

2.

[Progressive multifocal leukoencephalopathy after rituximab therapy in a patient with mantle cell lymphoma].

Ota I, Katsura Y, Yoshida C, Yoshizawa K, Ohtani H, Sata T, Komeno T.

Rinsho Ketsueki. 2010 Dec;51(12):1786-8. Japanese.

PMID:
21258190
3.

Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.

Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, Tai DW, Quek R, Tao M, Lim ST.

Ann Hematol. 2011 Oct;90(10):1219-23. doi: 10.1007/s00277-011-1241-0. Epub 2011 Apr 26.

PMID:
21520001
4.

[Efficiency therapy with rituximab in patients with non-Hodgkin's lymphomas].

Kriachok IA, Filonenko KS, Gubareva GO, Tytorenko IB, Novosad OI, Kadnikova TV, Aleksik OM, Martynchyk AV, Kushchevyĭ ÉV, Pastushenko IaV, Kutsenko LB.

Lik Sprava. 2011 Jan-Mar;(1-2):117-21. Ukrainian.

PMID:
21954645
5.

Pharmaceutical follow-up for patients on rituximab therapy for non-Hodgkin lymphoma: what is the evidence?

Hegele V, Stoll P, Wüst D, Ehrenbrink G, Grazziotin LR, Caregnato JP, Lindenmeyer LP.

Int J Clin Pharm. 2013 Aug;35(4):513-9. doi: 10.1007/s11096-013-9780-1. Epub 2013 Jun 5. Review.

PMID:
23737385
6.
7.

[Rituximab in the treatment of indolent non-Hodgkin's lymphoma].

Aurer I, Mitrović Z, Radman I, Kovacević-Metelko J, Nemet D, Serventi-Seiwerth R, Stern-Padovan R, Jakic-Razumović J, Nola M, Zupancić-Salek S, Sertić D, Labar B.

Lijec Vjesn. 2004 Nov-Dec;126(11-12):307-11. Croatian.

PMID:
16082888
8.

The therapeutic use of rituximab in non-Hodgkin's lymphoma.

Marcus R, Hagenbeek A.

Eur J Haematol Suppl. 2007 Jan;(67):5-14. Review.

PMID:
17206982
9.

Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis.

Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, Perry A, Yerra R, Schmidt R, Alvarez E, Tyler KL.

Arch Neurol. 2011 Sep;68(9):1156-64. doi: 10.1001/archneurol.2011.103. Epub 2011 May 9.

10.

[Rapid-progressive decrease of cognitive and physical functions in a B-cell non-Hodgkin's lymphoma patient treated with rituximab/bendamustine].

Küllmer A, Herrmann G, Riecken B.

Dtsch Med Wochenschr. 2013 Jun;138(25-26):1355-9. doi: 10.1055/s-0033-1343241. Epub 2013 Jun 12. German.

PMID:
23761057
12.

Peri-infusional adverse reactions to rituximab in patients with non-Hodgkin's lymphoma.

Arredondo-Garza T, Majluf-Cruz A, Vela-Ojeda J, Mariscal-Ramírez I, Solis-Anaya L, Lopez-Gutiérrez JR, Guadarrama CH, Rico-Curiel E, Armenta-San Sebastián JA, Castañeda-Hernández G.

Arch Med Res. 2013 Oct;44(7):549-54. doi: 10.1016/j.arcmed.2013.09.011. Epub 2013 Oct 8.

PMID:
24120421
13.

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL.

Blood. 2009 May 14;113(20):4834-40. doi: 10.1182/blood-2008-10-186999. Epub 2009 Mar 5.

14.

A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.

Molina A.

Annu Rev Med. 2008;59:237-50. doi: 10.1146/annurev.med.59.060906.220345. Review.

PMID:
18186705
15.

Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.

Fanale MA, Younes A.

Drugs. 2007;67(3):333-50. Review.

PMID:
17335294
16.

Cardiovascular adverse events complicating the administration of rituximab: report of two cases.

Passalia C, Minetto P, Arboscello E, Balleari E, Bellodi A, Del Corso L, Molinari E, Ponassi I, Oneto C, Sicbaldi V, Ghio R.

Tumori. 2013 Nov-Dec;99(6):288e-92e. doi: 10.1700/1390.15471.

PMID:
24503806
17.

Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.

Griffin MM, Morley N.

Expert Opin Biol Ther. 2013 May;13(5):803-11. doi: 10.1517/14712598.2013.786698. Review.

PMID:
23560506
18.

Feasibility and toxicity of concomitant radio/immunotherapy with MabThera (Rituximab®) for patients with non-Hodkin's Lymphoma: results of a prospective phase I/II study.

Haidenberger A, Fromm-Haidenberger S, de Vries A, Popper BA, Steurer M, Skvortsova I, Kantner J, Gunsilius E, Lukas P.

Strahlenther Onkol. 2011 May;187(5):300-5. doi: 10.1007/s00066-011-2169-y. Epub 2011 Apr 26.

PMID:
21544528
19.

Rituximab tolerability when given before or after CHOP.

Hannawa IS, Bestul DJ.

J Oncol Pharm Pract. 2011 Dec;17(4):381-6. doi: 10.1177/1078155210386989. Epub 2010 Nov 25.

PMID:
21109616
20.

Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease.

Gérard L, Michot JM, Burcheri S, Fieschi C, Longuet P, Delcey V, Meignin V, Agbalika F, Chevret S, Oksenhendler E, Galicier L.

Blood. 2012 Mar 8;119(10):2228-33. doi: 10.1182/blood-2011-08-376012. Epub 2012 Jan 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk